Mentioned in

References in periodicals archive

A total of 117 patients diagnosed with depression were randomly divided in two groups: Group I (58 patients) received Tablet amisulpride 50 mg/day orally and Group II (59 patients) were given Tablet escitalopram 10 mg/day orally.

Comparative evaluation of amisulpride and escitalopram on Hamilton Depression Rating Scale among depression patients in a tertiary care teaching hospital in Nepal

The subjects were divided into three groups, two were double blinded and received Escitalopram or placebo and one was non-blinded and underwent therapy with problem solving techniques.

Should I prevent my patient from developing depression after stroke? What is the best available option?

Lenze and his colleagues showed that during a lead-in phase with 12 weeks of open-label escitalopram, patients showed a modest reduction in worry symptoms on the Penn State Worry Questionnaire, but if they then had CBT added, they showed a substantial further reduction in worry, compared with those who did not receive CBT.

To manage anxiety, start with an SSRI and add CBT

Pharmacologic options beyond the three SSRIs backed by placebo-controlled, randomized trial evidence sertraline, citalopram, and escitalopram --include the various other SSRIs.

Expert offers tips on managing late-life anxiety

A 15-year-old Caucasian female with a past medical history significant for depression presented to the emergency department following a suicide attempt after ingesting approximately 500 milligrams of escitalopram. She presented with lethargy and dizziness.

Drug-induced QT prolongation as a result of an escitalopram overdose in a patient with previously undiagnosed congenital long QT syndrome

Individuals with any of the following conditions were excluded: (a) serious suicidal ideation based on the clinician's evaluation; (b) any serious physical illness; (c) any history of epilepsy; (d) history of closed-angle glaucoma; (e) abuse of or dependence on alcohol or any psychoactive drug during the past year; (f) depressive episode induced by other mental or physical illnesses; (g) lactation, current pregnancy, or any possible pregnancy during the trial; (h) history of severe drug allergy; or (i) a history of poor response to escitalopram.

Efficacy and safety of generic escitalopram versus Lexapro in the treatment of major depression: a multicenter double-blinded randomized controlled trial

Perlis cautions that the results of this study should not cause patients taking citalopram or escitalopram to stop taking their medication.

Antidepressant Celexa may up risk of irregular heartbeat

Separately, the FDA has approved the first genetic Lexapro (escitalopram tablets) to treat depression and generalized anxiety disorder in adults.

First-time generics hit the market

In May 2002, Lundbeck granted a licence for escitalopram -- the active ingredient in Lexapro -- in Japan to Mochida, which in January 2010 signed an agreement to co-market the drug with Mitsubishi Tanabe Pharma.

-Lundbeck's antidepressant Lexapro gets approval in Japan

The selective serotonin reuptake inhibitor escitalopram rapidly reduces the frequency and severity of hot flashes in menopausal women, according to a report.

SSRI escitalopram rapidly eases hot flashes

Rhabdomyolysis and Acute Renal Failure in a Recurrent Depressive Patient Treated with Escitalopram and Quetiapine: Case Report

Rabdomiolisis y falla renal aguda en un paciente con trastorno depresivo recurrente tratado con escitalopram y quetiapina